下肢血运重建术后90天再干预的相关因素
基于血管质量倡议与医疗保险和医疗补助服务中心链接数据,纳入2010年1月1日至2018年12月31日65岁及以上因外周动脉疾病行开放、腔内或杂交血运重建的42,429例患者,90天再干预率为14.5%,30天为5.5%;门诊或办公室实验室手术的90天和30天再干预风险显著高于住院手术。
要点
- 90天再干预率为14.5%,30天再干预率为5.5%。
- 门诊手术90天再干预HR为1.41,办公室实验室为2.09。
- 开放和杂交入路较腔内手术再干预风险更低。
核心结论
- 门诊外周动脉疾病干预可能与后续再干预的显著风险相关,需要进一步工作以了解如何提高门诊外周动脉疾病干预的持久性。
研究设计与样本
- 全国队列研究,纳入血管质量倡议与医疗保险和医疗补助服务中心链接数据集中2010年1月1日至2018年12月31日期间因外周动脉疾病行开放、腔内或杂交血运重建的65岁及以上成人,排除急性肢体缺血和动脉瘤手术,共42,429例。
主要发现
- 42,429例患者中,腔内手术占71.3%,开放手术占23.3%,杂交手术占5.4%;中位年龄74岁(四分位距69-80岁),男性占57.9%,白人占84.3%。
- 慢性肢体威胁性缺血为40.4%手术的手术指征;42.8%在门诊完成(40.3%门诊,2.5%办公室实验室)。
- 慢性肢体威胁性缺血的手术超过70%作为住院完成,而间歇性跛行干预60%作为门诊完成。
- 与住院手术相比,门诊手术90天再干预HR为1.41(95%CI 1.25-1.60),30天再干预HR为1.90(95%CI 1.62-2.24);办公室实验室手术90天再干预HR为2.09(95%CI 1.82-2.41),30天再干预HR为3.54(95%CI 3.17-3.94)。
- 开放和杂交入路在30天和90天再干预风险低于腔内手术;与主髂动脉疾病相比,所有其他解剖段疾病与更高的90天再干预相关,但30天无差异。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Peripheral artery disease (PAD) represents a high-volume, high-cost burden on the health care system. The Centers for Medicare and Medicaid Services has developed the Bundled Payments for Care Improvement-Advanced program, in which a single payment is provided for all services administered in a postsurgical 90-day episode of care. Factors associated with 30- and 90-day reinterventions after PAD interventions would represent useful data for both payors and stake holders. METHODS: We conducted a national cohort study of adults 65 years and older in the Vascular Quality Initiative and Centers for Medicare and Medicaid Services-linked dataset who underwent an open, endovascular, or hybrid revascularization procedure for PAD between January 1, 2010, and December 31, 2018. Procedures for acute limb ischemia and aneurysms were excluded. The primary outcome was 90-day reintervention. Reintervention at 30 days was a secondary outcome. Covariates of interest included demographics, comorbidities, and patient- and facility-level characteristics. Multivariable Cox regression was used to determine the association between patient- and facility-level characteristics and the risk of 30- and 90-day reinterventions. RESULTS: Among 42,429 patients (71.3% endovascular, 23.3% open, and 5.4% hybrid), median age was 74 years (interquartile range, 69-80 years), 57.9% were male, and 84.3% were White. Chronic limb-threatening ischemia was the operative indication in 40.4% of the procedures. Overall, 42.8% were completed in the outpatient setting (40.3% outpatient, 2.5% office-based lab). Over 70% of procedures for chronic limb-threatening ischemia were completed as inpatient, whereas 60% of the claudication interventions were done as outpatient. The 90-day reintervention rate was 14.5%, and the 30-day reintervention rate was 5.5%. Compared with inpatient procedures, PAD interventions completed in the outpatient or office-based lab setting had significantly higher 90- and 30-day reintervention rates (reference, inpatient; outpatient 90-day reintervention: hazard ratio [HR], 1.41; 95% confidence interval [CI] 1.25-1.60; outpatient 30-day reintervention: HR, 1.90; 95% CI, 1.62-2.24; office-based lab 90-day reintervention: HR, 2.09; 95% CI, 1.82-2.41; office-based lab 30-day reintervention: HR, 3.54; 95% CI, 3.17-3.94). Open and hybrid approaches demonstrated lower risk of reintervention compared with endovascular procedures at 30 and 90 days and, compared with aortoiliac disease, all other anatomic segments of disease were associated with higher 90-day reintervention, but no difference was noted at 30 days. CONCLUSIONS: Although outpatient PAD interventions may be convenient for patients and providers, the outpatient setting is associated with a significant risk of subsequent reintervention. Additional work is needed to understand how to improve the longevity of outpatient PAD interventions.
引用
- Alabi O, Harding JL, Massarweh N, et al. Factors associated with 90-day reintervention following lower extremity revascularization. J Vasc Surg. 2024. PMID: 38462063. doi:10.1016/j.jvs.2024.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。